AKR1C3 As A Potential Biomarker For Sensitivity Of T-lineage Acute Lymphoblastic Leukaemia To The Pre-prodrug PR-104
Funder
National Health and Medical Research Council
Funding Amount
$327,797.00
Summary
Multiagent chemotherapy is the most effective modality for the treatment of childhood ALL, the most common paediatric malignancy. Despite dramatic improvements in survival over the past 40 years, relapsed ALL remains one of the most common causes of death from disease in children. Therefore, innovative strategies are needed to benefit those children who respond poorly to established therapy. This application will test a novel therapy for a very aggressive subtype of childhood leukaemia.
Elucidating The Role Of Claudin-2 In Tumour Initiation And Metastasis Development From Colorectal Cancer: Consequence For Tumour Relapse
Funder
National Health and Medical Research Council
Funding Amount
$398,993.00
Summary
Mortality from colorectal cancer is often due to the development of metastases. Cancer stem cells (CSC) are suspected to provide a major drive for metastasis development, to resist current therapies, and to initiate tumour relapse. Yet, little is known about mechanisms that control CSC behaviour. Our project investigates the role of claudin-2, a cell adhesion protein that is strongly overexpressed in colorectal cancer, in the regulation of CSCs, metastasis development and tumour relapse.